<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82786">
  <stage>Registered</stage>
  <submitdate>28/04/2008</submitdate>
  <approvaldate>18/08/2008</approvaldate>
  <actrnumber>ACTRN12608000403336</actrnumber>
  <trial_identification>
    <studytitle>Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer</studytitle>
    <scientifictitle>Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone to establish disease-free survival outcomes in locally advanced rectal cancer (PETACC-6)</scientifictitle>
    <utrn />
    <trialacronym>PETACC-6</trialacronym>
    <secondaryid>Nil</secondaryid>
    <secondaryid>NCT00766155</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Rectal cancer</healthcondition>
    <healthcondition>Locally Advanced Rectal Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Radiotherapy: 0.8 Gy per fraction given every week day for 5 weeks, total of 45 Gy in 25 fractions.
Capecitabine: (oral tablets) 1650mg/m2 daily on day 1-33 pre-operatively and 2000mg/m2 daily from day 1 to day 15 for 6 21-day cycles post-operatively
AND Oxaliplatin: (intravenously) 50mg/m2 on days 1, 8, 15, 22, and 29 pre-operatively and 130mg/m2 on day 1 for 6 21-day cycles post-operatively.</interventions>
    <comparator>Radiotherapy: 0.8 Gy per fraction given every week day for 5 weeks, total of 45 Gy in 25 fractions.
Capecitabine: (oral tablets) 1650mg/m2 daily on day 1-33 pre-operatively and 2000mg/m2 daily from day 1 to day 15 for 6 21-day cycles post-operatively.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Disease-free survival, defined as the time interval from randomisation to the first event of loco-regional failure, metastatic recurrence, the appearance of a secondary colorectal cancer or death.</outcome>
      <timepoint>During Treatment: 4-8 weeks after surgery and at the end of last cycle of chemotherapy; or as indicated if suspected progression. Follow-up: every 3 months for 3 years, then every 6 months for years 4-5, or as required if suspected progression.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>Every 3 months for 3 years then every 6 months thereafter. Patient followed-up for survival for a minimum of 5 years, however follow-up until death is desirable.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Loco-regional failure. Measured via Computed tomography (CT) scan.</outcome>
      <timepoint>During Treatment: 4-8 weeks after surgery and at the end of last cycle of chemotherapy; or as indicated if suspected progression.
Follow-up: every 3 months for 3 years, then every 6 months for years 4-5,  or as required if suspected progression.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Distant failure. Measured via CT scan.</outcome>
      <timepoint>During Treatment: 4-8 weeks after surgery and at the end of last cycle of chemotherapy; or as indicated if suspected progression.
Follow-up: every 3 months for 3 years, then every 6 months for years 4-5,  or as required if suspected progression.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pathological downstaging rate, complete remission rate and tumor regression grade. Measured via CT scan.</outcome>
      <timepoint>Following pre-operative treatment, within 1 week prior to surgery.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Histopathological R0 resection rate</outcome>
      <timepoint>At surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Sphincter preservation rate. Assessed through surgery reports and physical examination.</outcome>
      <timepoint>At baseline and surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Perioperative complication rate (e.g. infection, surgery-associated bleeding, renal failure, deep venous thromboembolism, etc.). Assessed through surgery reports and physical examination.</outcome>
      <timepoint>Within 30 days post surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Toxicity. Assessed through physical examination and patient reports.</outcome>
      <timepoint>Weekly during chemoradiation treatment, within 1 week before surgery, 4-8 weeks post-surgery, before each cycle during post-operative chemotherapy and at the end of the last cycle of chemotherapy. During follow-up, every 3 months for the first 3 years, then every 6 months for years 4-5.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.Male or female patients with histologically proven adenocarcinoma of the rectum (tumour = 12 cm from the anal verge as assessed by rigid proctoscopy)
2.T3/4 or any node-positive disease 
3.No evidence of metastatic disease 
4.The disease must be considered either resectable at the time of entry or expected to become resectable after preoperative chemoradiation.
5.Age = 18 years.
6.World Health Organisation (WHO) / Eastern Cooperative Oncology Group (ECOG) Performance Status = 2
7.No prior cytotoxic chemotherapy or radiotherapy for rectal cancer.
8.No prior radiotherapy of the pelvis, for any reason.
9.Presence of adequate contraception in fertile patients. Pregnant or breastfeeding women are excluded from participation.
10.Adequate bone marrow, hepatic and renal function:
11.Haemoglobin = 10.0 g/dL, absolute neutrophil count = 1.5 x 109/L, platelet count = 100 x 109/L,
12. Alanine transaminase (ALAT)and aspartate transaminase (ASAT) = 2.5 x ULN
13.Alkaline phosphatase = 2.5 x ULN
14.Total bilirubin = 1.5 x ULN
15.Creatinine clearance &gt; 50 mL/min 
16.Creatinine = 1.5 x ULN
17.Ability to swallow tablets
18.Written informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Pregnant or breastfeeding women or fertile patients not using adequate contraception. 
2.Prior cytotoxic chemotherapy or radiotherapy for rectal cancer.
3.Prior radiotherapy of the pelvis, for any reason.
4. Previous (within the last 5 years) or concurrent malignancies.
5.Clinically significant (i.e. active) cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmia not well controlled with medication) or myocardial infarction within the last 12 months.
6.Significant impairment of intestinal resorption (e.g. chronic diarrhoea, inflammatory bowel disease).
7.Pre-existing condition which would deter chemoradiotherapy or radiotherapy, i.e. fistulas, severe ulcerative colitis (particularly patients currently taking Sulphasalazine), Crohns disease, prior adhesions. 
8.Peripheral neuropathy = grade 2 (according to Common Terminology Criteria for Adverse Events (CTCAE) v3.0).
9.History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant precluding informed consent or interfering with compliance for oral drug intake.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients will be centrally randomised via online randomisation system.</concealment>
    <sequence>A minimization technique will be used for random treatment allocation stratifying by treating center, clinical T category (T1-3 vs. T4), clinical nodal status (Nx vs. N0 vs.N1-2), distance from the tumor to the anal verge (&lt;=5 cm vs. &gt;5 cm), availability of Magnetic Resonance Imaging (MRI) at the center (yes vs. no).</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/11/2008</anticipatedstartdate>
    <actualstartdate>27/05/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate>9/09/2011</actualenddate>
    <samplesize>1090</samplesize>
    <actualsamplesize>1090</actualsamplesize>
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>TAS,NSW,VIC,QLD,SA,WA</recruitmentstate>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Australasian Gastro-Intestinal Trials Group (AGITG)</primarysponsorname>
    <primarysponsoraddress>AGITG Coordinating Centre
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown NSW 1450</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Cancer Australia</fundingname>
      <fundingaddress>Level 1, 243 Northbourne Avenue
Lyneham Canberra ACT</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>European Organisation for Research and Treatment of Cancer (EORTC)</sponsorname>
      <sponsoraddress>Avenue Mounierlaan, 83/11
Brussel 1200 Bruxelles</sponsoraddress>
      <sponsorcountry>Belgium</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will be used to investigate whether the addition of oxaliplatin to preoperative fluoropyrimidine-based
chemoradiation and postoperative fluoropyrimidine-based chemotherapy improves disease-free survival in locally advanced rectal cancer.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Cancer Institute NSW Clinical Research Ethics Committee</ethicname>
      <ethicaddress>Cancer Institute NSW
PO Box 41, Alexandria NSW 1435</ethicaddress>
      <ethicapprovaldate>1/07/2008</ethicapprovaldate>
      <hrec>2008C/01/039</hrec>
      <ethicsubmitdate>20/12/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>SLHD Ethics Review Committee RPAH Zone</ethicname>
      <ethicaddress>c/- Research Development Office
Royal Prince Alfred Hospital
Missenden Road, Camperdown NSW 2050
</ethicaddress>
      <ethicapprovaldate />
      <hrec>X13-0183</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Ms</title>
      <name>PETACC-6 Trial Coordinator</name>
      <address>AGITG Coordinating Centre 
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown NSW 1450</address>
      <phone>(02) 9562 5000</phone>
      <fax>(02) 9562 5094</fax>
      <email>petacc6@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>PETACC-6 Trial Coordinator</name>
      <address>AGITG Coordinating Centre
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown NSW 1450</address>
      <phone>(02) 9562 5000</phone>
      <fax>(02) 9562 5094</fax>
      <email>petacc6@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>PETACC-6 Trial Coordinator</name>
      <address>AGITG Coordinating Centre
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown NSW 1450</address>
      <phone>(02) 9562 5000</phone>
      <fax>(02) 9562 5094</fax>
      <email>petacc6@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Tim Price</name>
      <address>AGITG Coordinating Centre NHMRC Clinical Trials Centre Locked Bag 77 Camperdown NSW 1450</address>
      <phone>+61295625000</phone>
      <fax />
      <email>Timothy.Price@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>